Glenmark Pharmaceuticals Limited

rs,

bruary 14, 2024 To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai – 400 001 To, The Manager – Listing, National Stock Exchange of Indi

100%

ed Strategic Restructuring For Sharper Focus On The Three Businesses Alliance between GPL and its 100% subsidiary, Ichnos Sciences Inc. Innovation biotech focused on development of novel molecules as

82.84%

n biotech focused on development of novel molecules as potential treatment options for oncology (82.84% subsidiary) Focused on manufacturing and marketing of API products across all the major global m

3 million

year 2025** Zero waste to landfill at all our plant locations by the year 2027 Aspire to impact 3 million lives by 2025 Deepen global presence and deliver quality affordable in new markets Continue focu

Rs. 29,096

ed Q3 & 9M FY24 Summary – Consolidated (GPL + GLS) Q3 FY24 9M FY24  Revenue from operations at Rs. 29,096 Mn with decline of 16%  Revenue from operations at Rs. 98,991 Mn with growth of YoY due to one-

16%

solidated (GPL + GLS) Q3 FY24 9M FY24  Revenue from operations at Rs. 29,096 Mn with decline of 16%  Revenue from operations at Rs. 98,991 Mn with growth of YoY due to one-time impact on India b

Rs. 98,991

FY24  Revenue from operations at Rs. 29,096 Mn with decline of 16%  Revenue from operations at Rs. 98,991 Mn with growth of YoY due to one-time impact on India business 2.9%  Excluding the impact, appr

2.9%

nue from operations at Rs. 98,991 Mn with growth of YoY due to one-time impact on India business 2.9%  Excluding the impact, approx. revenue growth estimated to be  Excluding the one-time impact i

9%

venue growth estimated to be  Excluding the one-time impact in Q3 FY24, approx. revenue around 9% YoY growth estimated to be around 12% YoY  Consolidated Revenue of Rs. 29,096 Mn; decline of 16%

12%

ding the one-time impact in Q3 FY24, approx. revenue around 9% YoY growth estimated to be around 12% YoY  Consolidated Revenue of Rs. 29,096 Mn; decline of 16% YoY due to one-time impact in India

28.9%

Mn; decline of 16% YoY due to one-time impact in India business   Europe business growth of 28.9% YoY ROW business growth of 10.8% YoY  Adjusted EBITDA* of Rs. 289 Mn  R&D expenses of Rs. 3,08

10.8%

ne-time impact in India business   Europe business growth of 28.9% YoY ROW business growth of 10.8% YoY  Adjusted EBITDA* of Rs. 289 Mn  R&D expenses of Rs. 3,088 Mn  Capex of Rs. 2,368 Mn  C